hrcak mascot   Srce   HID

Izvorni znanstveni članak
https://doi.org/10.20471/acc.2021.60.02.01

Efficacy of Cyclocryotherapy and Transscleral Diode Laser Cyclophotocoagulation in the Management of Refractory Glaucoma

Aleksandar Miljković   ORCID icon orcid.org/0000-0003-1509-5041 ; Faculty of Medicine, University of Novi Sad, Novi Sad, Vojvodina, Serbia; Eye Department, Clinical Centre of Vojvodina, Novi Sad, Vojvodina, Serbia
Nikola Babić   ORCID icon orcid.org/0000-0002-4733-5786 ; Faculty of Medicine, University of Novi Sad, Novi Sad, Vojvodina, Serbia; Eye Department, Clinical Centre of Vojvodina, Novi Sad, Vojvodina, Serbia
Vladimir Čanadanović ; Faculty of Medicine, University of Novi Sad, Novi Sad, Vojvodina, Serbia; Eye Department, Clinical Centre of Vojvodina, Novi Sad, Vojvodina, Serbia
Sofija Davidović   ORCID icon orcid.org/0000-0002-7597-0437 ; Faculty of Medicine, University of Novi Sad, Novi Sad, Vojvodina, Serbia; Eye Department, Clinical Centre of Vojvodina, Novi Sad, Vojvodina, Serbia
Jelena Ljikar ; Eye Department, Clinical Centre of Vojvodina, Novi Sad, Vojvodina, Serbia
Marija Vasin ; Faculty of Medicine, University of Novi Sad, Novi Sad, Vojvodina, Serbia

Puni tekst: engleski, pdf (268 KB) str. 171-176 preuzimanja: 64* citiraj
APA 6th Edition
Miljković, A., Babić, N., Čanadanović, V., Davidović, S., Ljikar, J. i Vasin, M. (2021). Efficacy of Cyclocryotherapy and Transscleral Diode Laser Cyclophotocoagulation in the Management of Refractory Glaucoma. Acta clinica Croatica, 60. (2.), 171-176. https://doi.org/10.20471/acc.2021.60.02.01
MLA 8th Edition
Miljković, Aleksandar, et al. "Efficacy of Cyclocryotherapy and Transscleral Diode Laser Cyclophotocoagulation in the Management of Refractory Glaucoma." Acta clinica Croatica, vol. 60., br. 2., 2021, str. 171-176. https://doi.org/10.20471/acc.2021.60.02.01. Citirano 03.12.2021.
Chicago 17th Edition
Miljković, Aleksandar, Nikola Babić, Vladimir Čanadanović, Sofija Davidović, Jelena Ljikar i Marija Vasin. "Efficacy of Cyclocryotherapy and Transscleral Diode Laser Cyclophotocoagulation in the Management of Refractory Glaucoma." Acta clinica Croatica 60., br. 2. (2021): 171-176. https://doi.org/10.20471/acc.2021.60.02.01
Harvard
Miljković, A., et al. (2021). 'Efficacy of Cyclocryotherapy and Transscleral Diode Laser Cyclophotocoagulation in the Management of Refractory Glaucoma', Acta clinica Croatica, 60.(2.), str. 171-176. https://doi.org/10.20471/acc.2021.60.02.01
Vancouver
Miljković A, Babić N, Čanadanović V, Davidović S, Ljikar J, Vasin M. Efficacy of Cyclocryotherapy and Transscleral Diode Laser Cyclophotocoagulation in the Management of Refractory Glaucoma. Acta clinica Croatica [Internet]. 2021 [pristupljeno 03.12.2021.];60.(2.):171-176. https://doi.org/10.20471/acc.2021.60.02.01
IEEE
A. Miljković, N. Babić, V. Čanadanović, S. Davidović, J. Ljikar i M. Vasin, "Efficacy of Cyclocryotherapy and Transscleral Diode Laser Cyclophotocoagulation in the Management of Refractory Glaucoma", Acta clinica Croatica, vol.60., br. 2., str. 171-176, 2021. [Online]. https://doi.org/10.20471/acc.2021.60.02.01

Sažetak
Treating advanced glaucoma often requires numerous therapeutic modalities in
order to achieve the desired intraocular pressure (IOP) reduction. The purpose of this study was to
evaluate the IOP lowering efficacy of both cyclocryotherapy (CCT) and transscleral diode laser cyclophotocoagulation
(TS-DCPC) in the management of refractory primary open-angle glaucoma. This
prospective, randomized, controlled clinical trial included 40 patients (40 eyes) with refractory glaucoma
treated at the Eye Department, Clinical Center of Vojvodina, Novi Sad, Serbia, between January
2016 and June 2019. Twenty patients underwent CCT (group 1), while another twenty patients were
treated with TS-DCPC (group 2). Each patient underwent complete eye examination on the treatment
day, as well as follow-up eye examinations 7 days and 1, 6 and 12 months after the intervention,
when IOP and number of anti-glaucoma drugs used were recorded. The median baseline IOP was
36.50 mm Hg (IQR, 28.75-42.00) in group 1 and 27.00 mm Hg (IQR, 22.00-35.00) in group 2.
Follow-up measurements of IOP in group 1 showed the following results: 16.50 mm Hg (IQR, 7.75-
20.00) (60% decrease from the baseline value), 12.00 mm Hg (IQR, 9.25-18.00) (67% decrease from
the baseline value), 9.00 mm Hg (IQR, 2.00-13.75) (73% decrease from the baseline value), and 9.50
(IQR, 2.50-12.00) (75% decrease from the baseline value) after 7 days, 1, 6 and 12 months, respectively.
Follow-up measurements of IOP in group 2 showed the following results: 16.00 mm Hg (IQR,
10.00-17.00) (48% decrease from the baseline value), 14.00 mm Hg (IQR, 10.00-16.00) (56% decrease
from the baseline value), 14.00 mm Hg (IQR, 12.25-16.50) (43% decrease from the baseline
value) and 14.00 mm Hg (IQR, 11.25-15.75) (53% decrease from the baseline value) after 7 days, 1,
6 and 12 months, respectively. The mean number of antiglaucoma drugs used decreased from 4 to
0.65±0.81 and 2.25±1.07 in groups 1 and 2, respectively. In conclusion, study results confirmed the
CCT and TS-DCPC to have a rapid and statistically significant ocular hypotensive effect in eyes with
refractory glaucoma at one-year follow-up.

Ključne riječi
Refractory glaucoma; Cyclocryotherapy; Diode laser cyclophotocoagulation; Intraocular pressure

Hrčak ID: 263317

URI
https://hrcak.srce.hr/263317

[hrvatski]

Posjeta: 188 *